Methods to Discover and Validate Biofluid-Based Biomarkers in Neurodegenerative Dementias

Charlotte E. Teunissen; Leighann Kimble; Sherif Bayoumy; Katharina Bolsewig; Felicia Burtscher; Salomé Coppens; Shreyasee Das; Dea Gogishvili; Bárbara Fernandes Gomes; Nerea Gómez de San José; Ekaterina Mavrina; Francisco J. Meda; Pablo Mohaupt; Sára Mravinacová; Katharina Waury; Anna Lidia Wojdała; Sanne Abeln; Davide Chiasserini; Christophe Hirtz; Lorenzo Gaetani; Lisa Vermunt; Giovanni Bellomo; Steffen Halbgebauer; Sylvain Lehmann; Anna Månberg; Peter Nilsson; Markus Otto; Eugeen Vanmechelen; Inge M.W. Verberk; Eline Willemse; Henrik Zetterberg

doi:10.1016/j.mcpro.2023.100629

Methods to Discover and Validate Biofluid-Based Biomarkers in Neurodegenerative Dementias

Charlotte E. Teunissen^*, Leighann Kimble, Sherif Bayoumy, Katharina Bolsewig, Felicia Burtscher, Salomé Coppens, Shreyasee Das, Dea Gogishvili, Bárbara Fernandes Gomes, Nerea Gómez de San José, Ekaterina Mavrina, Francisco J. Meda, Pablo Mohaupt, Sára Mravinacová, Katharina Waury, Anna Lidia Wojdała, Sanne Abeln, Davide Chiasserini, Christophe Hirtz, Lorenzo GaetaniLisa Vermunt, Giovanni Bellomo, Steffen Halbgebauer, Sylvain Lehmann, Anna Månberg, Peter Nilsson, Markus Otto, Eugeen Vanmechelen, Inge M.W. Verberk, Eline Willemse, Henrik Zetterberg

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

Abstract

Neurodegenerative dementias are progressive diseases that cause neuronal network breakdown in different brain regions often because of accumulation of misfolded proteins in the brain extracellular matrix, such as amyloids or inside neurons or other cell types of the brain. Several diagnostic protein biomarkers in body fluids are being used and implemented, such as for Alzheimer’s disease. However, there is still a lack of biomarkers for co-pathologies and other causes of dementia. Such biofluidbased biomarkers enable precision medicine approaches for diagnosis and treatment, allow to learn more about underlying disease processes, and facilitate the development of patient inclusion and evaluation tools in clinical trials. When designing studies to discover novel biofluidbased biomarkers, choice of technology is an important starting point. But there are so many technologies to choose among. To address this, we here review the technologies that are currently available in research settings and, in some cases, in clinical laboratory practice. This presents a form of lexicon on each technology addressing its use in research and clinics, its strengths and limitations, and a future perspective.

Original language	English
Article number	100629
Journal	Molecular and Cellular Proteomics
Volume	22
Issue number	10
DOIs	https://doi.org/10.1016/j.mcpro.2023.100629
Publication status	Published - Oct 2023

Bibliographical note

Publisher Copyright:
© 2023 THE AUTHORS. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.

Funding

This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement number 860197. Conflicts of interest—S. D. is an employee of ADx NeuroSciences, Gent, Belgium. S. C. is an employee of National Measurement Laboratory at LGC, London, UK. C. E. T. has a collaboration contract with ADx Neurosciences, Quanterix and Eli Lilly, performed contract research or received grants from AC-Immune, Axon Neurosciences, BioConnect, Biogen, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, Peo-pleBio, Quanterix, Roche, Toyama, Vivoryon. She serves on editorial boards of Medidact Neurologie/Springer, Alzheimer Research and Therapy, Neurology: Neuroimmunology & Neuroinflammation, and is editor of a Neuromethods book Springer. E. V. is a co-founder of ADx NeuroSciences. H. Z. has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, NervGen, Novo Nordisk, OptoCeutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, AlzeCure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). All other authors declare that they have no conflicts of interest with the contents of this article.

Funders	Funder number
AC Immune SA
Eli Lilly and Company
Horizon 2020	860197

Access to Document

10.1016/j.mcpro.2023.100629Licence: CC BY

1-s2.0-S1535947623001408-mainFinal published version, 2.29 MBLicence: CC BY

Cite this

Teunissen, C. E., Kimble, L., Bayoumy, S., Bolsewig, K., Burtscher, F., Coppens, S., Das, S., Gogishvili, D., Gomes, B. F., de San José, N. G., Mavrina, E., Meda, F. J., Mohaupt, P., Mravinacová, S., Waury, K., Wojdała, A. L., Abeln, S., Chiasserini, D., Hirtz, C., ... Zetterberg, H. (2023). Methods to Discover and Validate Biofluid-Based Biomarkers in Neurodegenerative Dementias. Molecular and Cellular Proteomics, 22(10), Article 100629. https://doi.org/10.1016/j.mcpro.2023.100629

@article{34f2a337afd3446fa44454e5fb3fbcad,

title = "Methods to Discover and Validate Biofluid-Based Biomarkers in Neurodegenerative Dementias",

abstract = "Neurodegenerative dementias are progressive diseases that cause neuronal network breakdown in different brain regions often because of accumulation of misfolded proteins in the brain extracellular matrix, such as amyloids or inside neurons or other cell types of the brain. Several diagnostic protein biomarkers in body fluids are being used and implemented, such as for Alzheimer{\textquoteright}s disease. However, there is still a lack of biomarkers for co-pathologies and other causes of dementia. Such biofluidbased biomarkers enable precision medicine approaches for diagnosis and treatment, allow to learn more about underlying disease processes, and facilitate the development of patient inclusion and evaluation tools in clinical trials. When designing studies to discover novel biofluidbased biomarkers, choice of technology is an important starting point. But there are so many technologies to choose among. To address this, we here review the technologies that are currently available in research settings and, in some cases, in clinical laboratory practice. This presents a form of lexicon on each technology addressing its use in research and clinics, its strengths and limitations, and a future perspective.",

author = "Teunissen, {Charlotte E.} and Leighann Kimble and Sherif Bayoumy and Katharina Bolsewig and Felicia Burtscher and Salom{\'e} Coppens and Shreyasee Das and Dea Gogishvili and Gomes, {B{\'a}rbara Fernandes} and {de San Jos{\'e}}, {Nerea G{\'o}mez} and Ekaterina Mavrina and Meda, {Francisco J.} and Pablo Mohaupt and S{\'a}ra Mravinacov{\'a} and Katharina Waury and Wojda{\l}a, {Anna Lidia} and Sanne Abeln and Davide Chiasserini and Christophe Hirtz and Lorenzo Gaetani and Lisa Vermunt and Giovanni Bellomo and Steffen Halbgebauer and Sylvain Lehmann and Anna M{\aa}nberg and Peter Nilsson and Markus Otto and Eugeen Vanmechelen and Verberk, {Inge M.W.} and Eline Willemse and Henrik Zetterberg",

note = "Publisher Copyright: {\textcopyright} 2023 THE AUTHORS. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.",

year = "2023",

month = oct,

doi = "10.1016/j.mcpro.2023.100629",

language = "English",

volume = "22",

journal = "Molecular and Cellular Proteomics",

issn = "1535-9476",

publisher = "American Society for Biochemistry and Molecular Biology Inc.",

number = "10",

}

Teunissen, CE, Kimble, L, Bayoumy, S, Bolsewig, K, Burtscher, F, Coppens, S, Das, S, Gogishvili, D, Gomes, BF, de San José, NG, Mavrina, E, Meda, FJ, Mohaupt, P, Mravinacová, S, Waury, K, Wojdała, AL, Abeln, S, Chiasserini, D, Hirtz, C, Gaetani, L, Vermunt, L, Bellomo, G, Halbgebauer, S, Lehmann, S, Månberg, A, Nilsson, P, Otto, M, Vanmechelen, E, Verberk, IMW, Willemse, E & Zetterberg, H 2023, 'Methods to Discover and Validate Biofluid-Based Biomarkers in Neurodegenerative Dementias', Molecular and Cellular Proteomics, vol. 22, no. 10, 100629. https://doi.org/10.1016/j.mcpro.2023.100629

TY - JOUR

T1 - Methods to Discover and Validate Biofluid-Based Biomarkers in Neurodegenerative Dementias

AU - Teunissen, Charlotte E.

AU - Kimble, Leighann

AU - Bayoumy, Sherif

AU - Bolsewig, Katharina

AU - Burtscher, Felicia

AU - Coppens, Salomé

AU - Das, Shreyasee

AU - Gogishvili, Dea

AU - Gomes, Bárbara Fernandes

AU - de San José, Nerea Gómez

AU - Mavrina, Ekaterina

AU - Meda, Francisco J.

AU - Mohaupt, Pablo

AU - Mravinacová, Sára

AU - Waury, Katharina

AU - Wojdała, Anna Lidia

AU - Abeln, Sanne

AU - Chiasserini, Davide

AU - Hirtz, Christophe

AU - Gaetani, Lorenzo

AU - Vermunt, Lisa

AU - Bellomo, Giovanni

AU - Halbgebauer, Steffen

AU - Lehmann, Sylvain

AU - Månberg, Anna

AU - Nilsson, Peter

AU - Otto, Markus

AU - Vanmechelen, Eugeen

AU - Verberk, Inge M.W.

AU - Willemse, Eline

AU - Zetterberg, Henrik

PY - 2023/10

Y1 - 2023/10

N2 - Neurodegenerative dementias are progressive diseases that cause neuronal network breakdown in different brain regions often because of accumulation of misfolded proteins in the brain extracellular matrix, such as amyloids or inside neurons or other cell types of the brain. Several diagnostic protein biomarkers in body fluids are being used and implemented, such as for Alzheimer’s disease. However, there is still a lack of biomarkers for co-pathologies and other causes of dementia. Such biofluidbased biomarkers enable precision medicine approaches for diagnosis and treatment, allow to learn more about underlying disease processes, and facilitate the development of patient inclusion and evaluation tools in clinical trials. When designing studies to discover novel biofluidbased biomarkers, choice of technology is an important starting point. But there are so many technologies to choose among. To address this, we here review the technologies that are currently available in research settings and, in some cases, in clinical laboratory practice. This presents a form of lexicon on each technology addressing its use in research and clinics, its strengths and limitations, and a future perspective.

AB - Neurodegenerative dementias are progressive diseases that cause neuronal network breakdown in different brain regions often because of accumulation of misfolded proteins in the brain extracellular matrix, such as amyloids or inside neurons or other cell types of the brain. Several diagnostic protein biomarkers in body fluids are being used and implemented, such as for Alzheimer’s disease. However, there is still a lack of biomarkers for co-pathologies and other causes of dementia. Such biofluidbased biomarkers enable precision medicine approaches for diagnosis and treatment, allow to learn more about underlying disease processes, and facilitate the development of patient inclusion and evaluation tools in clinical trials. When designing studies to discover novel biofluidbased biomarkers, choice of technology is an important starting point. But there are so many technologies to choose among. To address this, we here review the technologies that are currently available in research settings and, in some cases, in clinical laboratory practice. This presents a form of lexicon on each technology addressing its use in research and clinics, its strengths and limitations, and a future perspective.

UR - http://www.scopus.com/inward/record.url?scp=85175064161&partnerID=8YFLogxK

U2 - 10.1016/j.mcpro.2023.100629

DO - 10.1016/j.mcpro.2023.100629

M3 - Review article

C2 - 37557955

AN - SCOPUS:85175064161

SN - 1535-9476

VL - 22

JO - Molecular and Cellular Proteomics

JF - Molecular and Cellular Proteomics

IS - 10

M1 - 100629

ER -

Methods to Discover and Validate Biofluid-Based Biomarkers in Neurodegenerative Dementias

Abstract

Bibliographical note

Funding

Access to Document

Other files and links

Fingerprint

Cite this